MALAYSIAN government-linked private equity company Ekuiti Nasional (Ekuinas) said on Tuesday (May 28) it aimed to expand its investment activity into private credit with an allocation of RM800 million (S$230 million).
Shahril Ridza Ridzuan, the new chairman of Ekuinas, was CEO of EPF from 2013 to 2018, and managing director of sovereign wealth fund Khazanah Nasional.
streetAsia s premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. SUBSCRIBE NOW
Singapore Reporter/s
In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digi
Malaysia’s government-owned private equity company Ekuiti Nasional (Ekuinas) has acquired a controlling stake in local drug firm Medispec for an undisclosed sum, marking its first investment in the pharmaceutical industry.
The acquisition was based on an enterprise value of 88.5 million ringgit (US$21.82 million) for Medispec, Ekuinas says in a statement on February 3. It did not disclose the size of the stake.
“Ekuinas’ entry into the healthcare and pharmaceutical space is timely as we look to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19,” Chief Executive Officer Syed Yasir Arafat Syed Abd Kahir says in the statement.